Similar articles

• Telmisartan, ramipril, or both in patients at high risk for vascular events.

  ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. ONTARGET Investigators, et al. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31. N Engl J Med. 2008. PMID: 18378520 Clinical Trial.
• Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

  Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators. Mann JF, et al. Lancet. 2008 Aug 16;372(9638):547-53. doi: 10.1016/S0140-6736(08)61236-2. Lancet. 2008. PMID: 18707986 Clinical Trial.
• Proteinuria: Is the ONTARGET renal substudy actually off target?

  Ruggenenti P, Remuzzi G. Ruggenenti P, et al. Nat Rev Nephrol. 2009 Aug;5(8):436-7. doi: 10.1038/nrneph.2009.109. Nat Rev Nephrol. 2009. PMID: 19639016 No abstract available.
• Telmisartan in high-risk cardiovascular patients.

  Weber MA. Weber MA. Am J Cardiol. 2010 Jan 4;105(1 Suppl):36A-43A. doi: 10.1016/j.amjcard.2009.10.008. Am J Cardiol. 2010. PMID: 20102972 Review.
• Telmisartan prevents cardiovascular events in a broad group of at-risk patients.

  Baumhäkel M, Böhm M. Baumhäkel M, et al. Expert Opin Pharmacother. 2009 Dec;10(18):3113-7. doi: 10.1517/14656560903449231. Expert Opin Pharmacother. 2009. PMID: 19925045 Review.